Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was co... Tweetable abstract Immunogenicity developed with CoronaVac in 25 (59.5%) of 42 patients who received at least one cytotoxic drug and in all patients (n = 5) who received monoclonal antibody or immu...

Objective: The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxaliplatin (FOLFOX) regimens in clinical practice according to their efficacy and toxicity. Methods: Patients who received oxaliplatin-containing regimens after curative resection for colorectal carcinoma from 10 different oncology centers between May 2004 and December 2009 were included in the study. All patients were treated with FOLFOX regimens. Patients with rectal carcinoma were also treated with chemoradiotherapy with 5-FU after 2 cycles of a FOLFOX regimen. Results: The median age of the patients was 56 years (range 17–78). Of the total 667 patients, 326 were given FOLFOX-4, 232 were given modified FOLFOX-4 and 109 were given FOLFOX-6. The distribution according to disease stage was 33 patients with stage IIIA colorectal cancer, 382 patients with stage IIIB and 252 patients with stage IIIC. The most common adverse events were neutropenia (54%), nausea (36.9%), neuropathy (38.2%) and anemia (33.1%) for all grades. The median follow-up time was 23 months (range 1–79). Three-year disease-free survival and overall survival were 65 and 85.7%, respectively. Conclusion: The different oxaliplatin-containing 5-FU-based adjuvant chemotherapy regimens in patients with stage III colorectal cancer seemed to be at least equal in terms of efficacy regardless of the method of 5-FU administration or oxaliplatin dose.

Primary gastrointestinal system lymphomas constitute about one third of all extranodal lymphomas. Duodenal involvement of the lymphoma is a rare condition. Periampullary lymphoma or lymphomatous involvement of ampulla of Vater is even rarer. Since, periampullary lymphoma is not easy to differentiate from epithelial carcinoma of these sites clinically and radiologically, accurate histopathological diagnosis is essential to plan optimal treatment strategy. Obstructive jaundice and the need for some form of drainage procedure and dose modification of the chemotherapy are additional challenges. In this report, we present three cases of duodenal diffuse large cell lymphoma with involvement of ampulla of Vater, two of whom presented with the initial signs of obstructive jaundice. One of the icteric patients was only diagnosed histopathologically following an explorative laparotomy with the initial diagnosis of carcinoma.

In our study, we determined the changes in the oxidative stress (OxS) biomarkers, thiol-disulfide (TD) homeostasis and ischemia-modified albumin (IMA) levels, in patients diagnosed with ovarian carcinoma before and after chemotherapy. We will examine the indirect effects of chemotherapy on OxS and antioxidant capacity by measuring changes in these blood biomarkers and compare the results with those of the healthy control group. This case–control study, which was conducted in a single-center, prospective design, included 42 patients diagnosed with ovarian cancer and 51 healthy volunteers. Venous blood samples were taken from all participants after 8 h of fasting, their serum was separated, and the serum total thiol, native thiol, disulfide, and IMA values were measured. In the comparison of the blood samples taken before the chemotherapy treatment of the patient group with the healthy control group, the native thiol (p < 0.001), total thiol (p < 0.001), and native thiol/total thiol (p < 0.001) values were found to be statistically significantly lower, and the disulfide (p = 0.001), disulfide/native (p < 0.001), and disulfide/total thiol (p < 0.001) levels were found to be statistically significantly greater. In the patient group diagnosed with ovarian cancer, a statistically significant difference was detected between the measurements of cancer antigen-125 (CA-125) (p < 0.001), native thiol (p = 0.019), and total thiol (p = 0.025) values at the 0th month before chemotherapy treatment and the third month after chemotherapy treatment. In the group that received adjuvant chemotherapy after the operation, the native thiol (p = 0.035), total thiol (p = 0.043), disulfide/native thiol (p = 0.035), disulfide total thiol (p = 0.035), native thiol/total thiol (p = 0.035) and IMA (p = 0.026) values were statistically significantly different between the diagnosis and third-month values. Our study suggests that TD homeostasis may be an important guide in terms of disease progression, complications during chemotherapy treatment, appropriate dose reductions, and modifications in chemotherapy depending on the toxicities experienced and the goals of the treatment.

Background: In this study, we aimed to investigate the frequency, prognostic effect of codon, and amino acid specific KRAS mutations in patients with metastatic colorectal cancer (mCRC) and their predictive effect on irinotecan and oxaliplatin during first-line treatment. Methods: The data of 304 mCRC patients were retrospectively evaluated between 2010 and 2018. Patients were categorized according to the most prominent codon and amino acid mutation and their prognostic features were analyzed. Results: In total, 274 patients were included in the study and 128 patients (47%) revealed KRAS mutation. Median follow-up time was 19.8 months (range; 1.6–96). The median overall survival rates for patients with codons 12 and 13 mutations were 25.4 and 22.2 months, respectively (p = 0.4). Moreover, the median overall survival for the codon 12 mutant patients who received irinotecan-based chemotherapy in the first-line treatment was 42.7 months, whereas for the codon 13 mutant and KRAS wild-type patients, it was 18.3 and 23.9 months, respectively (codon 12 vs. codon 13; HR: 0.31, p = 0.03, codon 12 vs. wild-type; HR: 0.45, p = 0.03). Conclusion: The significant survival advantage was observed in patients with codon 12 mutations who received irinotecan-based chemotherapy as a first-line treatment.